Spero Therapeutics/ US84833T1034 /
2024-05-20 9:57:43 PM | Chg. -0.03 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
1.55USD | -1.90% | 3,197 Turnover: 4,959.23 |
-Bid Size: - | -Ask Size: - | 1.58 | 1.53 |
GlobeNewswire
05-16
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
GlobeNewswire
05-15
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
GlobeNewswire
05-08
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wed...
GlobeNewswire
05-01
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
03-13
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Busi...
GlobeNewswire
03-06
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial...
GlobeNewswire
02-28
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infect...
GlobeNewswire
01-31
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
01-02
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipe...
GlobeNewswire
2023-11-21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possib...
GlobeNewswire
2023-11-13
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
GlobeNewswire
2023-11-06
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Mon...
GlobeNewswire
2023-11-01
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
GlobeNewswire
2023-10-31
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-09-29
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-09-20
Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference
GlobeNewswire
2023-09-12
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of ...
GlobeNewswire
2023-09-06
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire
2023-09-05
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Sco...
GlobeNewswire
2023-08-31
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)